Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Optimization in screening and...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Optimization in screening and diagnosis of Prostate Cancer (PCa): Use of Prostate Health Index (PHI) and mMRI in biopsy-naive patients

Optimization in screening and diagnosis of Prostate Cancer (PCa): Use of Prostate Health Index (PHI) and mMRI in biopsy-naive patients

Bibliographic Details
Main Authors: E. Fernández Guzman, M. Domínguez Esteban, P. Calleja Hermosa, C. Redondo Figuero, R. Varea Malo, E. Alonso Mediavilla, N. García Formoso, E. Ramos Barseló, E. Herrero Blanco, G. Velilla Díez, F. Campos Juanatey, S. Zubillaga Guerrero, R. Ballestero Diego, P. Lastra García-Barón, A. Azueta Etxebarria, J.L. Gutiérrez Baños
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320326549
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320326549

Similar Items

  • Robotic retroperitoneal partial nephrectomy for a horseshoe kidney
    by: N. García Formoso, et al.
    Published: (2020-11-01)
  • Recent Advances in Prostate Cancer (PCa) Diagnostics
    by: Ahmad Abdelrazek, et al.
    Published: (2022-06-01)
  • Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
    by: Matteo Ferro, et al.
    Published: (2013-01-01)
  • Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    by: Shui, I, et al.
    Published: (2014)
  • Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium
    by: Shui, I, et al.
    Published: (2014)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs